Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Johnson and Johnson
McKinsey
Medtronic
Baxter

Last Updated: November 29, 2021

DrugPatentWatch Database Preview

Patent: 9,295,682

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 9,295,682
Title:Adjuvant immunotherapy for the preventive, curative or palliative treatment of chronic systemic diseases such as cancer, of clinical manifestations associated with diseases like cachexia and correction of adverse effects of drugs such as immunosuppression, neutropenia and lymphopenia, comprising the association or combination of a biological response modifier specially selected and other substances with antineoplastic action and/or other treatments
Abstract: The present invention comprises a new combination or association of pharmacologically active substances and/or non-drug treatments for cancer. According to the present invention, the combination or association of substances and/or non-drug treatments is used to treat cancer, clinical problems associated to cancer and adverse side effects related to substances and/or treatments used to fight this illness. The components of the combination or association of substances, the biological response modifier (proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride) and at least one substance and/or treatment with antineoplastic properties can be jointly or simultaneously or consecutively or sequentially administered in an appropriate form, according to their chemical properties, and with the use of the most suitable procedures, and also in the most therapeutically effective dose and use.
Inventor(s): Nunes; Iseu da Silva (Campinas-Sao Paulo, BR)
Assignee:
Application Number:13/516,628
Patent Claims:see list of patent claims

Details for Patent 9,295,682

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Biogen Inc. AVONEX interferon beta-1a For Injection 103628 1996-05-17 ⤷  Try it Free 2039-02-26
Biogen Inc. AVONEX interferon beta-1a Injection 103628 2003-05-28 ⤷  Try it Free 2039-02-26
Biogen Inc. AVONEX interferon beta-1a Injection 103628 2012-02-27 ⤷  Try it Free 2039-02-26
Emd Serono, Inc. REBIF interferon beta-1a Injection 103780 2002-03-07 ⤷  Try it Free 2039-02-26
Emd Serono, Inc. REBIF interferon beta-1a Injection 103780 2004-12-17 ⤷  Try it Free 2039-02-26
Emd Serono, Inc. REBIF interferon beta-1a Injection 103780 2012-12-21 ⤷  Try it Free 2039-02-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Harvard Business School
Boehringer Ingelheim
Colorcon
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.